The founder contributed to a news flash on Alzforum on ‘Blood test granted breakthrough status’.
2013, 2 May, A new paper related to the evaluation of variability in CSF biomarker testing was published.
The founder contributed to a new paper in Alzheimer’s & Dementia, entitled ” CSF biomarker variability in the Alzheimer’s Association quality control program”.
2013, 6 April, A new publication on plasma amyloid beta in a longitudinal study (AIBL)
The founder was a co-author on a new paper in Alzheimer’s & Dementia, entitled “Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer’s disease”.
2013, 6 April, A new publication on assay validation for integration in clinical trials
The founder was a co-author on a publication in Journal of Alzheimer’s disease entitled “Validation of assays for measurement of Amyloid-β peptides in cerebrospinal fluid and plasma specimens from patients with Alzheimer’s disease treated with Solanezumab.”
2013, January 25, New Publication on CSF Harmonization
A new paper, entitled “Alzheimer disease biomarker testing in Cerebrospinal Fluid: a method to harmonize assay platforms in the absence of an absolute reference standard” was published by the founder in Clinical Chemistry.
2012, December – Publication – Validation multiplex Abeta plasma assay
A new paper, entitled “Validation of a multiplex assay for simultaneous quantification of amyloid-beta peptide species in human plasma with utility for measurements in studies of Alzheimer’s Disease Therapeutics” was published in Journal of Alzheimer’s.
2012, December – Publication – Technology comparison.
A new publication, entitled “Comparison of two analytical platforms for the clinical qualification of Alzheimer’s disease biomarkers in pathologically-confirmed dementia” was published in Journal of Alzheimer’s disease.
2012, May 30 – AlzForum
CBS Evening News Report – Potential New Alzheimer’s Test
“A recently-published medical journal study indicates a new test exists for detecting memory loss, which could potentially help diagnose early stages of Alzheimer’s disease. Dr. Jon LaPook reports.”